Education
About Us
Working with TipRanks
Follow Us
Inventiva (IVA)
NASDAQ:IVA
IVA Stock Chart & Stats
$4.46
-$0.02(-0.90%)
At close: 4:00 PM EST
$4.46
-$0.02(-0.90%)
Day’s Range― - ―
52-Week Range$2.11 - $7.98
Previous CloseN/A
Volume917.00
Average Volume (3M)99.38K
Market Cap
$843.26M
Enterprise Value$270.96M
Total Cash (Recent Filing)$122.08M
Total Debt (Recent Filing)$57.13M
Price to Earnings (P/E)―
Beta0.22
Next Earnings
Apr 01, 2026EPS Estimate
-0.34Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-1.62
Shares Outstanding191,077,500
10 Day Avg. Volume175,727
30 Day Avg. Volume99,378
Financial Highlights & Ratios
PEG Ratio-0.01
Price to Book (P/B)-1.01
Price to Sales (P/S)11.68
P/FCF Ratio-1.25
Enterprise Value/Market Cap0.32
Enterprise Value/Revenue24.82
Enterprise Value/Gross Profit27.82
Enterprise Value/Ebitda-0.97
Forecast
1Y Price Target
$17.86Price Target Upside300.45% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering7
EPS Forecast (FY)N/A
Revenue Forecast (FY)N/A
Bulls Say, Bears Say
Bulls Say
Clinical TrialsThe ongoing Phase III NATiV3 study is fully enrolled with a patient composition similar to the Phase IIb study, with expectations to duplicate strong efficacy findings.
Drug DevelopmentLanifibranor remains the only agent to hit both endpoints in a 24-week trial, showing a significant fibrosis improvement compared to placebo.
Market PotentialThe increased price target from $20 to $24 reflects the analyst's confidence in lanifibranor's potential as a prime acquisition candidate and its positioning as a cardiometabolic oral backbone.
Bears Say
Clinical ChallengesFibrosis has been the most difficult feature of MASH to address, but remains the most clinically relevant given its strong association with outcomes.
Safety ConcernsPioglitazone faces a number of tolerability/safety concerns that limit its use.
Stock Price DisparityIVA shares dropped significantly due to a disparity between the price of the ADR and shares traded on the Euronext Paris exchange.
Inventiva News
IVA FAQ
What was Inventiva’s price range in the past 12 months?
Inventiva lowest stock price was $2.11 and its highest was $7.98 in the past 12 months.
What is Inventiva’s market cap?
Inventiva’s market cap is $843.26M.
When is Inventiva’s upcoming earnings report date?
Inventiva’s upcoming earnings report date is Apr 01, 2026 which is in 106 days.
How were Inventiva’s earnings last quarter?
Inventiva released its earnings results on Sep 29, 2025. The company reported -$1.616 earnings per share for the quarter, missing the consensus estimate of -$0.63 by -$0.986.
Is Inventiva overvalued?
According to Wall Street analysts Inventiva’s price is currently Undervalued.
Does Inventiva pay dividends?
Inventiva does not currently pay dividends.
What is Inventiva’s EPS estimate?
Inventiva’s EPS estimate is -0.34.
How many shares outstanding does Inventiva have?
Inventiva has 191,077,500 shares outstanding.
What happened to Inventiva’s price movement after its last earnings report?
Inventiva reported an EPS of -$1.616 in its last earnings report, missing expectations of -$0.63. Following the earnings report the stock price went down -2.975%.
Which hedge fund is a major shareholder of Inventiva?
Currently, no hedge funds are holding shares in IVA
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Inventiva Stock Smart Score
Outperform
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
$17.86 (300.45% Upside)
$17.86 (300.45% Upside)
Crowd Wisdom
Neutral
Last 7 Days ▼ 0.8%
Last 30 Days ▲ 1.6%
Last 30 Days ▲ 1.6%
News Sentiment
Neutral
Bullish news 50%
Bearish news 50%
Bearish news 50%
Technicals
SMA
Positive
20 days / 200 days
Momentum
95.43%
12-Months-Change
Fundamentals
Return on Equity
―
Trailing 12-Months
Asset Growth
399.59%
Trailing 12-Months
Company Description
Inventiva
Inventiva (IVA) is a biopharmaceutical company focused on developing innovative therapies for patients with rare diseases and metabolic disorders. Established in France, the company operates primarily in the biotechnology sector, with a strong emphasis on research and development. Inventiva's core products include drug candidates that target conditions like non-alcoholic steatohepatitis (NASH) and other fibrotic diseases, leveraging its proprietary platforms to advance its pipeline of therapeutic solutions.
IVA Stock 12 Month Forecast
Average Price Target
$17.86
▲(300.45% Upside)
Technical Analysis
Iovance Biotherapeutics
―
Kura Oncology
―
Urogen Pharma
―
Maravai Lifesciences Holdings
―
MBX Biosciences, Inc.
―
Ownership Overview
―
Insiders
<0.01% Mutual Funds
3.31% Other Institutional Investors
96.69% Public Companies and Individual Investors
Options Prices
Currently, No data available
---